Quality of life research among melanoma patients that have been treated with immunotherapy, or targeted therapy and/or surgery
Recruiting
- Conditions
- Kwaliteit van LevenQuality of Life10040900
- Registration Number
- NL-OMON55207
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 700
Inclusion Criteria
- At least 18 years of age
- Actively treated for melanoma by use of immunotherapy, targeted therapy,
surgery or a combination.
- Willing to fill in one questionnaire and perform one online cognition test.
Exclusion Criteria
- Insufficient understanding of the Dutch or English language
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary study parameter is Health Related Quality of Life will be assessed<br /><br>with the he European Organization for Research and Treatment of Cancer Quality<br /><br>of Life Questionnaire-core 30 (EORTC QLQ-C30).</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary outcome measurements will be gained from the use of the following<br /><br>questionnaires: the Melanoma Subscale and Melanoma Surgery Subscale of the<br /><br>Functional Assessment of Cancer Therapy * Melanoma (FACT-M), five questions<br /><br>about sociodemographic data, the Hospital Anxiety and Depression Scale (HADS),<br /><br>the Cancer Worry Scale (CWS), the immunotherapy-specific questionnaire, 4<br /><br>questions about sexual health (EORTC sexuality module), social functioning<br /><br>(work ability) will be assessed with the work-ability questionnaire, patients<br /><br>will describe and value their experienced health (QUALY*s) with the 5-level<br /><br>EuroQOL-5D (EQ-5D-5L), and cognitive functioning will be assessed with the<br /><br>online Amsterdam Cognition Scan (ACS).</p><br>